Jafron Biomedical Co

Jafron Biomedical Co Capital Intensity

The Capital Intensity Ratio of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 268.86 %. In the previous year, Capital Intensity Ratio was 201.08 % — a change of 33.71% (higher).

Capital Intensity

268.86 %

YoY

33.71%

Last updated:

Capital Intensity Ratio of Jafron Biomedical Co is 2025 268.86 % . Capital Intensity Ratio of Jafron Biomedical Co was 2024 201.08 % . It decreases by 33.71% higher compared to the previous year.

The Jafron Biomedical Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
201.86 CNY
Jan 1, 2019
174.23 CNY
Jan 1, 2020
164.89 CNY
Jan 1, 2021
179.79 CNY
Jan 1, 2022
217.28 CNY
Jan 1, 2023
288.36 CNY
Jan 1, 2024
201.08 CNY
Jan 1, 2025
268.86 CNY
The Jafron Biomedical Co Capital Intensity history
YEARCapital IntensityYoY
268.86 %+33.71%
201.08 %-30.27%
288.36 %+32.71%
217.28 %+20.85%
179.79 %+9.03%
164.89 %-5.36%
174.23 %-13.69%
201.86 %-14.80%
236.94 %-0.90%
239.10 %+76.69%
135.32 %-6.87%
145.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Capital Intensity Ratio of Jafron Biomedical Co is 268.86 % in 2025.

Capital Intensity Ratio of Jafron Biomedical Co changed from 201.08 % to 268.86 %, representing a 33.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co